Germany’s Evotec says it has taken notice of the statement made by Halozyme Therapeutics on November 22, stating that it has withdrawn its non-binding proposal to acquire Evotec for 11.00 euros per ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback